BioSpace News Archive

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3 TOURMALINE-MM2 trial evaluating the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant

SonoScape Medical Corporation introduced its new generation high-end ultrasound systems: the ELITE series, integrating artificial intelligent solutions, advanced features, and remarkably improved system processing capability.

Natera, Inc., a global leader in cell-free DNA testing, announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock.

The New England Journal of Medicine published the full overall survival results from the pre-specified final OS analysis of the Phase III ARAMIS trial for NUBEQA® in men with non-metastatic castration-resistant prostate cancer.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 14-16, 2020 .

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to present at the 22nd H. C. Wainwright Annual Global Investment Conference, which is being held virtually on September 14-16, 2020.

Fountain Medical Development (FMD K&L), together with its affiliates, is rebranding as ClinChoice Inc (“ClinChoice” or “Company”). ClinChoice is a global clinical stage Contract Research Organization (“CRO”), with over 1800 clinical research professionals in seven different countries across North America, Asia and Europe.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2020 financial results on Thursday, October 29, 2020, at 7:30 a.m. Central Time.

Since 1889, Mentholatum® Cough and Cold products have provided soothing relief for families during cold and flu season with trusted formulas and innovative topical solutions